Arizona State Retirement System increased its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 7.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,800 shares of the medical equipment provider’s stock after buying an additional 1,200 shares during the period. Arizona State Retirement System’s holdings in ABIOMED were worth $2,103,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Gilder Gagnon Howe & Co. LLC increased its stake in ABIOMED by 320.1% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 8,272 shares of the medical equipment provider’s stock valued at $1,064,000 after buying an additional 6,303 shares during the period. Dimensional Fund Advisors LP increased its stake in ABIOMED by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 132,006 shares of the medical equipment provider’s stock valued at $14,875,000 after buying an additional 4,990 shares during the period. Creative Planning increased its stake in ABIOMED by 16.4% in the first quarter. Creative Planning now owns 916 shares of the medical equipment provider’s stock valued at $115,000 after buying an additional 129 shares during the period. World Asset Management Inc increased its stake in ABIOMED by 17.0% in the first quarter. World Asset Management Inc now owns 2,844 shares of the medical equipment provider’s stock valued at $356,000 after buying an additional 413 shares during the period. Finally, Marshall Wace LLP increased its stake in ABIOMED by 56.3% in the fourth quarter. Marshall Wace LLP now owns 55,113 shares of the medical equipment provider’s stock valued at $6,210,000 after buying an additional 19,858 shares during the period. 91.02% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

ABIOMED, Inc. (ABMD) traded up 0.36% on Friday, reaching $143.39. The company’s stock had a trading volume of 293,856 shares. The firm’s 50 day moving average price is $136.37 and its 200-day moving average price is $122.08. ABIOMED, Inc. has a 1-year low of $95.14 and a 1-year high of $145.58. The company has a market capitalization of $6.25 billion, a price-to-earnings ratio of 122.56 and a beta of 0.25.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, May 4th. The medical equipment provider reported $0.33 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.33. The firm had revenue of $124.68 million during the quarter, compared to the consensus estimate of $122.82 million. ABIOMED had a net margin of 11.70% and a return on equity of 12.67%. The firm’s revenue was up 32.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.24 earnings per share. Equities analysts forecast that ABIOMED, Inc. will post $1.84 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Arizona State Retirement System Boosts Position in ABIOMED, Inc. (ABMD)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/06/16/abiomed-inc-abmd-shares-bought-by-arizona-state-retirement-system-updated-updated.html.

Several equities research analysts have commented on ABMD shares. Piper Jaffray Companies raised ABIOMED from a “neutral” rating to an “overweight” rating and set a $145.00 target price on the stock in a report on Thursday, April 6th. TheStreet raised ABIOMED from a “c+” rating to a “b-” rating in a report on Tuesday, February 21st. William Blair reissued an “outperform” rating on shares of ABIOMED in a report on Thursday, June 8th. Finally, Leerink Swann upped their price target on ABIOMED from $140.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, March 30th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $151.00.

In related news, VP Michael G. Howley sold 18,279 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $133.56, for a total value of $2,441,343.24. Following the completion of the sale, the vice president now owns 62,105 shares in the company, valued at $8,294,743.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Michael G. Howley sold 600 shares of the firm’s stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $132.84, for a total transaction of $79,704.00. Following the completion of the sale, the vice president now owns 48,305 shares of the company’s stock, valued at approximately $6,416,836.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 53,629 shares of company stock valued at $7,072,580. 10.00% of the stock is owned by insiders.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Receive News & Stock Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related stocks with our FREE daily email newsletter.